BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will present new clinical data from three cornerstone hematology assets at the European Hematology Association ...

Among previously treated patients with HER2-mutated, advanced non-small cell lung cancer (NSCLC), treatment with zongertinib showed durable responses and clinically meaningful results, according to ...

Putting the MARIPOSA findings into perspective, Yang explained that 15 years ago, overall survival with the first-generation EGFR tyrosine kinase inhibitor gefitinib was 20 months. With the third ...

Callie Coombs, MD, and Brian Koffman, MD, provide an overview of chronic lymphocytic leukemia, mantle cell lymphoma, and small lymphocytic lymphoma, and explore the key differences between these ...

This enables them to switch the proliferation of these cells on and off. For this experiment, the scientists focused on non-small cell lung cancer (NSCLC), the most common type of lung cancer.

FLT3 is a receptor tyrosine kinase that plays a pivotal role in the normal development of hematopoietic stem cells and progenitor cells. FLT3 mutations occur in approximately 30% of all AML cases, ...

In accordance with these new discoveries in mice, Rbm25 activity is also negatively correlated with white blood cell counts that mark poor survival in human patients with myeloid leukemia.

Preliminary preclinical data have been reported for Enliven Therapeutics Inc.’s ATP-competitive small-molecule ABL1 tyrosine kinase inhibitor (TKI) ELVN-001. In vitro antiproliferative effects, ...

As the leukemia cells were now relying on the MEK/MAPK pathway for survival, the team used a second drug—a kinase inhibitor called trametinib—to block that pathway. This effectively cut off ...

Mobocertinib performed well and had a favorable safety profile in patients with platinum-pretreated EGFR exon 20 insertion–positive metastatic non-small cell lung cancer and could serve as a possible ...

Introduction Chronic myeloid leukemia (CML) is a clonal malignant disorder of pluripotent hematopoietic stem cells (HSCs), characterized by the presence of Philadelphia chromosome (Ph) translocation t ...